H. Léna

发表

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

C. Rudin, S. Gettinger, E. Felip, 2015, The New England journal of medicine.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Jean Mosser, Franck Morin, Gérard Zalcman, 2016, The Lancet.

INCREASED EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) EXPRESSION IN PULMONARY FIBROSIS

S. Guillot, V. Lagente, C. Martin-Chouly, 2006, Experimental lung research.

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

J. Mazières, C. Chouaid, A. Vergnenègre, 2015, BMC Cancer.

Systemic Capillary Leak Syndrome (Clarkson's Disease) as a Complication of Anti-Programmed Death 1 Immunotherapy.

C. Lescure, H. Léna, A. Lescoat, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin.

F. Brichory, H. Léna, L. Dazord, 1995, British Journal of Cancer.

Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1.

L. Thiberville, P. Souquet, P. Fournel, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[Parapneumonic pleural effusions: Epidemiology, diagnosis, classification and management].

J. Letheulle, Y. le Tulzo, H. Léna, 2015, Revue des maladies respiratoires.

[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].

A. Vergnenègre, H. Léna, G. Robinet, 2000, Revue des maladies respiratoires.

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes

N. Girard, D. Planchard, P. Dubray-Longeras, 2021, Targeted Oncology.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

N. Girard, O. Molinier, M. Denis, 2019, Clinical lung cancer.

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort.

N. Girard, M. Carton, R. Gervais, 2021, Lung cancer.

Genomic characteristics and clinical significance of CD56+ Circulating Tumor Cells in Small Cell Lung Carcinoma

M. Aubry, A. Chatziioannou, T. Guillaudeux, 2022 .

Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small–cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB)

C. Marquette, J. Vergnon, L. Thiberville, 2019, PloS one.

Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study.

J. Breau, D. Moro, H. Léna, 2002, Chest.

Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

B. Milleron, F. Barlesi, C. Chouaid, 2010 .

Endoscopic management of idiopathic tracheal stenosis.

M. Noppen, C. Marquette, J. Vergnon, 2011, The Annals of thoracic surgery.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Keunchil Park, N. Rizvi, J. Mazières, 2018, The Lancet. Oncology.

Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).

P. Fournel, A. Vergnenègre, H. Léna, 2006, Lung cancer.

Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases.

R. Fauchet, H. Léna, S. Caulet-Maugendre, 2002, Human immunology.

IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma (MPM).

J. Mazières, G. Zalcman, D. Moro-Sibilot, 2010 .

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

E. Baudin, T. Meyer, J. Mazières, 2017, The Lancet. Oncology.

O. Molinier, J. Mazières, G. Zalcman, 2019, Clinical Cancer Research.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

J. Milanowski, C. Gridelli, D. Atanackovic, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

J. Soria, J. Mazières, J. Trédaniel, 2015, Clinical Cancer Research.

EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature.

J. Mosser, A. Lespagnol, C. Dugast, 2015, Lung cancer.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

D. Gerber, I. Bondarenko, W. Su, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al.

A. Vergnenègre, H. Léna, R. Corre, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How old is "too old" for translational research?

A. Vergnenègre, H. Léna, R. Corre, 2014, Translational lung cancer research.

Genomic characteristics and clinical significance of CD56+ Circulating Tumor Cells in Small Cell Lung Carcinoma

M. Aubry, T. Guillaudeux, M. Logotheti, 2022, bioRxiv.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

R. Govindan, A. Dingemans, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Spontaneous splenic rupture as a rare complication of G-CSF injection

H. Léna, C. Ricordel, S. Benguerfi, 2018, BMJ Case Reports.

Iterative Thoracentesis as First-Line Treatment of Complicated Parapneumonic Effusion

J. Letheulle, Y. le Tulzo, H. Léna, 2014, PloS one.

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial

O. Molinier, J. Mazières, G. Zalcman, 2022, International journal of cancer.

Treatment of human lung carcinoma xenografts with a combination of 131I-labelled monoclonal antibody Po66 and doxorubicin

F. Brichory, H. Léna, P. Bourguet, 1997, Cancer Immunology, Immunotherapy.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

H. Léna, R. Corre, A. Salé, 2020, Clinical lung cancer.

Increased release of matrix metalloproteinase‐9 in the plasma of acute severe asthmatic patients

V. Lagente, E. Boichot, C. Belleguic, 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

Long-term nasal intermittent positive pressure ventilation (NIPPV) in sixteen consecutive patients with bronchiectasis: a retrospective study.

A. Gacouin, H. Léna, B. Desrues, 1996, The European respiratory journal.

High prevalence of undiagnosed COPD in a cohort of HIV-infected smokers

S. Eymard-Duvernay, F. Raffi, F. Bonnet, 2014, European Respiratory Journal.

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

M. Buyse, R. Ramlau, E. Stoelben, 2011, The Lancet. Oncology.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

E. Felip, J. Adam, A. Szczesna, 2016, The Lancet. Oncology.

105PDTG4010 IMMUNOTHERAPY COMBINED WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). PHASE 2B RESULTS OF THE TIME STUDY

J. Nemunaitis, J. Limacher, E. Quoix, 2015 .

Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

N. Girard, T. Molina, L. Thiberville, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): A French randomized phase III trial of GLOT-GFPC (NPC 95-01 study)

J. Daurès, P. Souquet, P. Fournel, 2001 .

Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study

E. Baudin, T. Meyer, J. Mazières, 2016 .

Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.

P. Souquet, D. Damotte, C. Chouaid, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[Adrenalectomy for adrenal metastases: is the laparoscopic approach beneficial for all patients?].

K. Bensalah, N. Rioux-Leclercq, B. Peyronnet, 2014, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors

J. Wanders, B. Darpo, A. Kristensen, 2013, Investigational New Drugs.

Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).

R. Govindan, J. Ahn, S. Ou, 2015 .

Severe diffuse interstitial pneumonitis induced by carmustine (BCNU).

H. Léna, B. Desrues, P. Delaval, 1994, Chest.

Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.

G. Ferretti, S. Lantuejoul, G. Vassal, 2015 .

156 Phase II study of docetaxel (Taxotere®) in 1st and 2nd line NSCLC

H. Léna, G. Robinet, P. Thomas, 1997 .

[Pulmonary metastases with a prolonged development. Two cases of thyroid cancers].

C. Belleguic, H. Léna, B. Desrues, 1996, Revue des maladies respiratoires.

Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus.

C. Lebbé, H. Léna, A. Lescoat, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Alveolar haemorrhage revealing epithelioid haemangioendothelioma.

H. Léna, B. Turlin, S. Caulet-Maugendre, 1997, Respiratory medicine.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Jie Yang, S. Ou, A. Dingemans, 2017, European journal of cancer.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study

Franck Morin, Patrick Merle, Pascal Auquier, 2018, European Respiratory Journal.

[Phase II study of docetaxel in inoperable advanced non small cell lung cancer].

A. Vergnenègre, H. Léna, G. Robinet, 2000, Bulletin du cancer.

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

C. Lázaro, G. Capellá, D. Planchard, 2020 .

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

J. Mosser, J. Mazières, J. Sabourin, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

A. Dingemans, J. Mazières, M. Schuler, 2022, Annals of Oncology.

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

J. Pignon, B. Milleron, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study

N. Rizvi, J. Mazières, J. Vansteenkiste, 2017 .

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

C. Chouaid, A. Vergnenègre, H. Léna, 2014, Lung cancer.

Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

N. Girard, L. Thiberville, B. Dubray, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

B. Milleron, M. Taron, G. Zalcman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

R. Govindan, J. Ahn, S. Ou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Roman K. Thomas, F. Cappuzzo, E. Smit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ING2 tumor suppressive protein translocates into mitochondria and is involved in cellular metabolism homeostasis

T. Guillaudeux, H. Léna, R. Pedeux, 2021, Oncogene.

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

R. Ramlau, M. Krzakowski, E. Tartour, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management of elderly patients.

A. Vergnenègre, H. Léna, R. Corre, 2013, Translational lung cancer research.

Unusual cause of recurrent pneumothorax: excavated metastasis of osteosarcoma.

P. Kerbrat, H. Léna, P. Delaval, 2001, The Annals of thoracic surgery.

Survival of patients with bronchiectasis after the first ICU stay for respiratory failure.

Rémi Thomas, A. Gacouin, G. Brinchault, 2004, Chest.

Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients. Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.

N. Rioux-Leclercq, H. Léna, Sarah Medane, 2017, Oncotarget.

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance

H. Léna, R. Pedeux, C. Ricordel, 2022, Frontiers in Oncology.

Un regard simple sur la biologie moléculaire du cancer bronchique : K-Ras

H. Léna, R. Corre, M. Denis, 2010 .

Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.

Melissa L. Johnson, C. H. van der Leest, B. Cho, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

C. Chouaid, R. Gervais, P. Saulnier, 2020, The Lancet. Oncology.

Azygos vein aneurysm: contribution of transesophageal echography.

D. Heresbach, H. Léna, H. Corbineau, 1996, The Annals of thoracic surgery.

Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next‐generation Sequencing

J. Mosser, A. Lespagnol, H. Hamdi-Rozé, 2017, Clinical lung cancer.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

J. Mosser, D. Planchard, J. Merlio, 2019, European journal of cancer.

First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial

J. Mazières, J. Spano, C. Audigier-Valette, 2020, European Respiratory Journal.

LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

N. Girard, C. Lepage, J. Mazières, 2021, Annals of Oncology.

[KRAS and bronchial adenocarcinoma. Between disappointments and hopes].

A. Didier, J. Mazières, P. Hofman, 2016, Revue des maladies respiratoires.

1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

A. Drilon, M. Awad, J. Gray, 2022, Annals of Oncology.

Efficacy and Safety of Onartuzumab in Combination With First‐Line Bevacizumab‐ or Pemetrexed‐Based Chemotherapy Regimens in Advanced Non‐Squamous Non–Small‐Cell Lung Cancer

H. Wakelee, S. Novello, F. D. De Braud, 2017, Clinical lung cancer.

Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.

P. Bondiau, L. Claude, J. Castelli, 2021, Lung cancer.

Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer

M. Aubry, T. Guillaudeux, M. Logotheti, 2023, bioRxiv.

Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): Randomized phase II trial GFPC-GLOT-IFCT 02-01.

P. Souquet, P. Fournel, C. Chouaid, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.

J. Daurès, P. Souquet, P. Fournel, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).

P. Preux, P. Fournel, A. Vergnenègre, 2005, Lung cancer.

Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer

J. Castelli, R. de Crevoisier, E. Chajon, 2018, Radiation Oncology.

An Original Case of an Association of Eosinophilic Fasciitis with Cholangitis Induced by Nivolumab.

P. Marcorelles, H. Léna, C. Ricordel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).

F. Barlesi, R. Gervais, H. Léna, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC‡ 04-2017).

A. Vergnenègre, H. Léna, G. Robinet, 2020, Future oncology.

Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease

V. Lagente, J. Planquois, C. Bertrand, 2004, Inflammation Research.

Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study.

J. Muir, H. Léna, G. Robinet, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

R. Govindan, S. Ou, A. Shaw, 2019, Lung cancer.

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.

J. Daurès, B. Massuti, R. Descourt, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study

F. Barlesi, P. Fournel, R. Descourt, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tracheobronchial stenting in patients with esophageal cancer involving the central airways.

C. Belleguic, H. Léna, J. Bretagne, 1999, Endoscopy.

Mycobacterium chelonae Pseudoepidemic Due to Contamination of Flexible Bronchoscopes

C. Belleguic, H. Léna, P. Donnio, 1998 .

30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)

G. Giaccone, C. Gridelli, T. Mok, 2018, ESMO Open.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

E. Felip, M. Hellmann, M. Chatterjee, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

J. Daurès, P. Souquet, P. Fournel, 2016, European journal of cancer.

Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01).

C. Combescure, P. Souquet, P. Fournel, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC). Interim analysis of toxicity. (GLOT-GFPC NPC 95-01 study)

J. Daurès, P. Souquet, P. Fournel, 2000 .

Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.

N. Girard, T. Filleron, H. Léna, 2023, Respiratory medicine and research.

Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.

J. Vernejoux, H. Léna, G. Robinet, 2002, Lung cancer.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

L. Thiberville, J. Mazières, D. Moro-Sibilot, 2018, ERJ Open Research.

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

G. Zalcman, P. Fournel, D. Pérol, 2012, BMC Cancer.

Exogenous lipoid pneumonia complicated by Mycobacterium fortuitum and Aspergillus fumigatus infections.

H. Léna, P. Donnio, B. Desrues, 1996, The European respiratory journal.

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

D. Gandara, D. Planchard, S. Ramalingam, 2014 .

Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer

J. Castelli, R. de Crevoisier, E. Chajon, 2018, Radiation oncology.

[Retrospective analysis of 50 thymic epithelial tumors in Rennes university hospital].

H. Léna, R. Corre, J. Verhoye, 2014, Revue des maladies respiratoires.

Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations

N. Rioux-Leclercq, H. Léna, Sarah Medane, 2017, Oncotarget.

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial

C. Dooms, Melissa L. Johnson, S. Novello, 2023, The Lancet.

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung

H. Léna, R. Corre, G. Robinet, 2020, JTO clinical and research reports.

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

R. Abgral, U. Schick, G. Quéré, 2020, Cancer medicine.

Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).

F. Guisier, C. Audigier-Valette, A. Vergnenègre, 2022, Journal of Clinical Oncology.

[Fire-eater's lung: report of six cases].

C. Belleguic, H. Léna, S. Birolleau, 1999, Revue de Pneumologie Clinique.

Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome.

C. Lázaro, G. Capellá, D. Planchard, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial.

P. Souquet, P. Fournel, H. Léna, 2002, Lung cancer.

Asymptomatic bronchial aspiration of a video capsule.

P. d'Halluin, H. Léna, S. Jouneau, 2009, Interactive cardiovascular and thoracic surgery.

OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab

Y. Shentu, R. Herbst, H. Saka, 2017 .

Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC

H. Léna, C. Ricordel, Y. Le Guen, 2023, Journal of Thoracic Oncology.

179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center

H. Léna, Y. L. Guen, C. Ricordel, 2021, Journal of Thoracic Oncology.

Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.

J. Vernejoux, P. Fournel, C. Belleguic, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort.

D. Pasquier, M. Carton, T. Filleron, 2023, Journal of geriatric oncology.

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

A. Dingemans, S. Ou, F. Barlesi, 2016 .

Coeliac-Like Disease Is a Rare Immune-Related Complication Induced by Nivolumab in NSCLC.

A. Lièvre, H. Léna, R. Corre, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer

H. Léna, MD Mark van Barele, MD Chistien C.M. Buis, 2021, Menopause.

[Pulmonary nocardiosis with cerebral abscesses mimicking metastatic lung cancer: Three cases and a review of literature].

H. Léna, R. Corre, S. Jouneau, 2017, Revue des maladies respiratoires.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

J. Mazières, O. Trifan, H. Léna, 2012 .

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies ( NP 28673 1 and NP 28761 ) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer

Jie Yang, R. Govindan, A. Shaw, 2017 .

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with measurable asymptomatic inoperable brain metastases (BM): A multicenter phase II trial (GFPC 07-01).

F. Barlesi, R. Gervais, H. Léna, 2010 .